上海医药：西格列汀二甲双胍缓释片获得批准生产

Core Viewpoint - Shanghai Pharmaceuticals (601607) announced that its subsidiary, Changzhou Pharmaceutical Factory Co., Ltd., has received a Drug Registration Certificate from the National Medical Products Administration for the production of Sitagliptin Metformin Extended-Release Tablets, which are approved for use in adult patients with type 2 diabetes who are undergoing combined treatment with Sitagliptin and Metformin Extended-Release Tablets [1] Group 1 - The approved drug is specifically indicated for adult patients with type 2 diabetes [1] - Sitagliptin Metformin Extended-Release Tablets were originally developed by Merck Sharp & Dohme and were launched in the United States in 2012 [1]